Member Info for Bobbler

RMM, much appreciated, treat yourself to pasty!

Hi Stoney, I’d don’t tweet, might be of interest to Dr Baiilie the author of the nature study ref tyk2.
https://mobile.twitter.com/kennethbaillie

https://www.bbc.co.uk/news/world-europe-57677178

With regards to Tax, SAR would only have a 10% corporation tax liability on any product sold (or income generated from patent ie license) which is subject to a U.K. granted patent (patent box). Could possibly be a reason to have an additional patent to cover the Covid element?? The mysterious patent maybe.

Very very tax inspectors at the revenue speak or read Japanese, my advice……they won’t know unless you tell them

https://mobile.twitter.com/Sareumplc

Stoney, agreed completely.

I can’t see how it can’t Ahfam. To much of an own goal for U.K. gov to ignore, if the US ran with it and it worked… after being ignored by the U.K.

“The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field.”

The only experts in the field of Covid trials to my mind is U.K. Gov, as they’re running the worlds biggest trials for Covid therapeutics.

“Inconclusive due to technical shortcomings in the disease model.”

The models (cells) are provided to Sar so sounds to me that is an issue out of their control.

A disease model is an animal or cells displaying all or some of the pathological processes that are observed in the actual human or animal disease.

I believe the inclusive bit is due to technical issues with the samples provided to SAR.

A disease model is an animal or cells displaying all or some of the pathological processes that are observed in the actual human or animal disease.

That’s a classic123 RNS :-)

I think they’re probably well down the road ref Agile.

Says it all

Classic123, your opinions are as welcome as anal discharge, please keep the dribble to yourself.

By far the most informative of “T”’s post to date

https://m.youtube.com/watch?v=meF7NmfnXZ0

Patrick Chinnery, Chair of UK-CTAP and Medical Research Council Clinical Director, explains how the panel reaches its conclusions on which treatments to prioritise:

Although there are similarities with other respiratory illnesses like flu and pneumonia, COVID-19 is a bit different. As well as damaging the lungs, the disease can also have an overwhelming effect on the immune system and cause blood clots, so we’re looking at drugs covering a range of disease mechanisms and modes of action.

For each potential treatment we’ll examine whether there is a plausible mechanism of action against COVID-19 or its complications, any evidence that it might work in COVID-19 patients, and whether it’s being tested anywhere else in the world.

We’ll also consider whether it’s a medicine that could actually be used in the NHS if it works – is it available, affordable and able to be manufactured at scale?

Looks like we’ve got pinky and perky today, what fun.
https://m.youtube.com/watch?v=ZMw5jzO_lv0

Or Carlsberg